Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD

  Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the European Respiratory Society (“ERS”) International Congress 2023. The abstract is available to conference attendees on the ERS website and will be published in an upcoming issue of the peer reviewed publication, European Respiratory Journal.

The presentation will highlight additional analyses of the ENHANCE-1 24-week exacerbation data which demonstrated treatment with ensifentrine resulted in a substantial decrease in the rate and risk of moderate COPD exacerbations as well as moderate and severe COPD exacerbations. Furthermore, it will highlight the impact of ensifentrine treatment on healthcare resource utilization related to COPD including fewer physician’s office visits, emergency department visits and hospitalizations compared with placebo treatment.

https://www.marketscreener.com/quote/stock/VERONA-PHARMA-PLC-34676176/news/Verona-Pharma-to-Present-Additional-Analysis-of-Phase-3-ENHANCE-1-Study-in-COPD-at-ERS-International-44777959/